Lumos Diagnostics Holdings (ASX:LDX) received a milestone payment of $507,377, under its contract with the Biomedical Advanced Research and Development Authority (BARDA) for achieving US Food and Drug Administration (FDA) CLIA waiver for its FebriDx rapid point-of-care test, according to a Thursday Australian bourse filing.
The receipt of the payment from BARDA brings the total amount received under the CLIA waiver study to almost $3 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.